2-[[(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S,3S)-2-[(2-hydrazinylacetyl)amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-N-[(2S)-1-oxo-1-[[1-oxo-3-[2-[(2,4,6-trimethoxyphenyl)methyl]-1H-indol-3-yl]propan-2-yl]amino]-3-phenylpropan-2-yl]butanediamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[[(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S,3S)-2-[(2-hydrazinylacetyl)amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-N-[(2S)-1-oxo-1-[[1-oxo-3-[2-[(2,4,6-trimethoxyphenyl)methyl]-1H-indol-3-yl]propan-2-yl]amino]-3-phenylpropan-2-yl]butanediamide
• 化学式: C₅₅H₇₇N₁₁O₁₄
• 分子量: 1116.3
• InChiKey: DPEXQUIAJFAVIB-CCVCLBQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  80
• 可旋转键数：
  33
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  386
• 氢给体数：
  13
• 氢受体数：
  16

文献信息

• VACCINE FOR A THERAPEUTIC OR A PROPHYLACTIC TREATMENT OF MYASTHENIA GRAVIS
  申请人：CuraVac Inc.

  公开号：US20140161831A1

  公开（公告）日：2014-06-12

  Complementary peptide having at least a sequence complementary to a major immunogenic region of an acetylcholine receptor involved in myasthenia gravis, characterized in that the complementary peptide has at least a sequence SEQ. ID. NO1 with a tryptophan in position 8, carrying at least one optionally substituted hydrocarbon group. Therapeutic composition comprising the Complementary peptide according to the invention and use thereof for manufacturing a vaccine to be used in a therapeutic or prophylactic treatment of myasthenia gravis in mammals.
• US9359406B2
  申请人：——

  公开号：US9359406B2

  公开（公告）日：2016-06-07